FAU creates start-up company to develop drugs to treat epilepsy, migraines and strokes
Florida Atlantic University has entered into a licensing agreement with Eco Neurologics, Inc., a start-up company based on FAU intellectual property, to develop novel drugs that are medically relevant for febrile epilepsy, migraine and brain injury during stroke.
Through the agreement, Ken Dawson-Scully, Ph.D., an assistant professor in biological sciences received a $353,000 sponsored research grant from Eco Neurologics, Inc. to support his laboratory at FAU and expand his patent portfolio in this scientific area. Dawson-Scully will serve as the lead scientific consultant to Eco Neurologics, Inc.
"We are at a critical stage in developing therapies for these devastating diseases, and this support will initiate a strong relationship between Eco Neurologics, Inc. and FAU," said Dawson-Scully. "This corporate relationship establishes the infrastructure for the company's success, and aligns FAU with the strategic plan of our neighboring institutes, The Scripps Research Institute Florida and The Max Planck Florida Institute for Neuroscience."
Dawson-Scully is one of six neuroscience investigators from FAU's Charles E. Schmidt College of Science who recently moved into a newly renovated state-of-the-art research building on the FAU MacArthur campus in Jupiter.
"This exciting collaboration is proof of the principle that clustering neuroscience expertise, through one of FAU's strategic signature themes, in this case the biotechnology signature theme, will lead to an innovative and productive research environment on the Jupiter campus," said Rod Murphey, Ph.D., department chair of the Department of Biological Sciences.
Eco Neurologics, Inc. is headquartered at the Research Park at Florida Atlantic University. The company's directors include Ferris H. Lander, a registered patent agent and entrepreneur with expertise in intellectual property business development and George Jackowski, Ph.D., a cardiovascular biochemist and serial entrepreneur with a long history of success in the biotechnology industry.